- XPEL Inc (NASDAQ:XPEL) reported second-quarter FY21 sales growth of 92% year-on-year, to $68.74 million, beating the analyst consensus of $57.78 million.
- Product revenue rose 89.5% Y/Y, and services revenue increased 107.9%.
- The gross margin for the quarter expanded 390 basis points to 36.7%.
- The operating margin was 18.4%, and operating income for the quarter rose 146% to $12.7 million.
- The company held $8.7 million in cash and equivalents as of June 30, 2021.
- EBITDA grew 139.8% to $13.6 million, with a margin of 19.8%, versus 15.8% last year.
- EPS of $0.37 beat the analyst consensus of $0.26.
- Price action: XPEL shares traded lower by 0.51% at $83.46 on the last check Monday.
These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)
What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.
